Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

March 10, 2023

Study Completion Date

February 28, 2024

Conditions
COVID-19Vaccines
Interventions
BIOLOGICAL

AdCLD-CoV19-1 OMI (Part A)

20 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle

BIOLOGICAL

AdCLD-CoV19-1 OMI (Part B)

250 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle

OTHER

Placebo (Part B)

50 participants will receive placebo via intramuscular injection in the deltoid muscle

Trial Locations (7)

Unknown

Hallym University Dongtan Sacred Heart Hospital, Gyeonggi-do

Korea University Ansan Hospital, Gyeonggi-do

The Catholic University of Korea ST. Vincent's Hospital, Gyeonggi-do

Gachon University Gil Medical Center, Incheon

Inha University Hospital, Incheon

Hallym University Kangnam Sacred Heart Hospital, Seoul

Korea University Guro Hospital, Seoul

All Listed Sponsors
lead

Cellid Co., Ltd.

INDUSTRY